OR WAIT null SECS
© 2021 MJH Life Sciences and Ophthalmology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
October 13, 2021
Cynthia Matossian, MD, FACS, ABES, takes a look at the recent, sudden change in low-payment reimbursement by Medicare Administrative Contractors for LipFlow and MGD procedure codes.
October 12, 2021
Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.
A simple solution that involves use of air filtration devices may help reduce the risk of hospital-acquired SARS-CoV-2 infections.
Aerie Pharmaceuticals announced Tuesday positive topline results for the phase 3 trial evaluating netarsudil 0.02% versus ripasudil 0.4% for the treatment of open-angle glaucoma and elevated IOP.
Changes in health care industry can affect the way ophthalmologists plan their finance.
October 11, 2021
The FDA approved Ocular Therapeutix Inc.’s Supplemental New Drug Application (sNDA) that further extends Dextenza’s (dexamethasone ophthalmic insert) 0.4 mg indications, the company announced Monday.
Merck and Ridgeback Biotherapeutics are seeking emergency use authorization for molnupiravir, an oral experimental antiviral treatment for mild-to-moderate COVID-19 in adults at risk for virus progression or hospitalization.
David Boyer, MD, reports on the use of pegcetacoplan to treat geographic atrophy when administered monthly or every-other-month regimens in the phase 3 DERBY and OAKS studies.
Arshad Khanani, MD, MA, reports primary study findings from the phase 3 study on the Port Delivery System with ranibizumab.
Investigators in the United Kingdom found that concomitant vaccination of flu and COVID-19 raised no safety concerns and preserved the immune response to both vaccines.